Podcasts about bristol myers squibb company

In this heartfelt episode of The Patient From Hell, host Samira Daswani talks to Jill Massey, a pharmacist and pharma industry veteran whose path through cancer has been both personal and professional. Jill shares her experiences as a caregiver for her sister, mother, and husband—all cancer patients—before becoming a patient herself. They discuss the emotional and practical challenges of navigating caregiving, the complexities of the healthcare system, and how Jill's unique perspective as both a medical professional and a patient shaped her approach to advocacy, treatment decisions, and resilience. Key Highlights: 1. A Personal and Professional Journey: Jill reflects on how her family's battles with cancer shaped her career in the pharmaceutical industry, blending personal empathy with professional expertise. 2. Balancing Roles and Emotions: From sibling to spouse to patient, Jill shares the unique emotional dynamics of each role and the coping mechanisms she developed. 3. Empowerment Through Knowledge: Jill emphasizes the importance of patient education, advocating for personalized care, and the evolving role of pharmaceutical companies in supporting patient-centric care. About our guest: Jill Massey, PharmD, MBA, BCMAS is Vice President, Global Medical Strategy and Operations (GMSO) for Gilead Medical Affairs.  In this role, Jill oversees the Patient-focused Implementation Science team, Medical Strategy and Planning, Insights, Data & Analytics and Digital Innovation, Medical Excellence, Medical Affairs Technology, and Scientific Communications including global publications, medical information, medical external affairs and education, and library and information services.   Jill joined Gilead Sciences from Immunomedics where she led the Medical Affairs, Safety and Pharmacovigilance organizations.  Prior to that, she led Medical Affairs at Janssen, The Medicines Company and Melinta Therapeutics as well as the Melinta Global Antimicrobial Resistance Program. She began her career in the pharmaceutical industry at Bristol-Myers Squibb Company.  Previous to her industry roles, Jill was clinical faculty at the Saint Louis College of Pharmacy, Jewish Hospital and the Program on Aging at Washington University School of Medicine.  Jill is a member of the Board of Directors for the Morris County Chamber of Commerce and serves on the Life Sciences Council Steering Committee.  She is a member of the National Advisory Committee for the Robert A. Winn Diversity in Clinical Trials Award Program, a member of the Accreditation Council of Medical Affairs Executive Leadership Board and a member of the Seton Hall University Transformative Leadership Advisory Board.   Jill earned her Doctor of Pharmacy degree from the University of Nebraska Medical Center and her MBA from Drexel University LeBow College of Business. She completed a residency at Mercer University School of Pharmacy and Emory University. She is Board Certified by ACMA.   Jill loves running, baking and spending time with her two kids, Maddie and Alex, and her loved ones, sometimes including her two dogs and cat. Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only.  This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Are you spending like other consumers? Retail sales in the month of October showed an impressive gain of 2.8% compared to last year. With lower gasoline prices, gas stations were a major negative as they declined 7.1% compared to last year. If this group was excluded from the headline number, retail sales would have been up an even more impressive 3.7%. There were several areas of strength as gains were quite broad across various industries, but nonstore retailers, which was up 7.0% and food services and drinking places, which was up 4.3% continued to lead the charge. Interestingly, both furniture and home furnishing stores, which was up 1.5% and building material and garden equipment and supplies dealers, which was up 2.8% showed annual gains for the first time in many months. I wouldn't necessarily say these categories are particularly strong, but it appears they may have finally bottomed. With that said, I do believe they could be areas of strength in 2025 considering they have both been depressed areas for a couple of years now and I believe people will look towards home improvement next year. Overall, this is further evidence that the consumer remains healthy and willing to spend in this economy.    How the tariffs with China could play out over the next few months I'm beginning to get questions from people who have concerns about the tariffs on China products such as when will they start? How much will they be and should I buy products such as appliances now before the tariffs on China begin? These are all great questions. It's important to understand the tariffs cannot be placed until after the inauguration of the Mr. Trump. It is possible on is his first day that could be one of the many things he will do when he is the official president. It is, however, possible that he may hold off on the tariffs because the purpose of tariffs is to force equal trade or free trade with China, and Mr. Trump may want to use tariffs as a negotiation tool. In 2023 the trade deficit with China was $279 billion. Mr. Trump wants China to import more goods from our economy, which was only $148 billion in 2023. This could come from such things as agricultural products and based on the amount of oil we could be pumping in 2025, we may have more oil than we can use here and maybe China will purchase some. There are also other products as well that will be on the table. It should also be noted last time Mr. Trump was in office, China's economy was very strong, and they were not as willing to negotiate. Fast forward to today and the Chinese economy has weakened. This could mean they would be more open to talk on trade to help their economy. No one knows exactly what the new president will do or how much the tariffs will be, but if you need to buy goods that are made in China, your window of opportunity may be running out!   Is inflation continuing to cool? The October Consumer Price Index (CPI) showed price gains came in line with expectations. Headline CPI increased 2.6% compared to last year and core CPI, which excludes food and energy climbed 3.3%. The headline CPI was above September's reading of 2.4% and core CPI matched September's reading of 3.3%. According to economists, the monthly inflation rate in October 2023 was unusually low, which made the October 2024 reading look relatively high. Hopefully, this means we will see further progress in the months ahead as core CPI has not shown much progress as of last as it has been stuck at 3.2% or 3.3% since May's 3.4% reading. While much of this sounds problematic, there are not many areas of concern when looking at the inflation report. The major issue continues to be shelter which rose 4.9% compared to last year and accounted for over 65% of the annual increase in core CPI. I continue to believe shelter inflation will eventually resolve itself, which would then bring the major inflation measures more in line with the Fed's desired level. Powell even said during a press conference, “Market rents, newly signed leases, are experiencing very low inflation." He also mentioned the current shelter inflation readings are due to a catch-up problem and "It's not really reflecting current inflationary pressures." I do believe with this report a December cut looks more likely, but that would not leave room for as many cuts in 2025. Based on the current data, I believe a Fed Funds Rate around 3.5% would be a fair level and that compares to a current Fed Funds Rate of 4.5-4.75%. That means if there is a cut in December, we could be looking at maybe just 3 or 4 rate cuts next year.    Work Income vs Retirement Income When planning for retirement, it's important to understand the difference between your work income and your retirement income. If you get paid $200k/year, close to $17k/month, after taxes and savings, your net paycheck might be closer to $120k/year or $10k/month. If you go into retirement with the idea that you need to replace that entire $200k of income to continue your lifestyle, that's just not true. In retirement you are not paying payroll taxes, which in California is a flat rate of 8.75%, you're typically not saving much anymore, and if planned properly, you're paying less federal and state taxes as well. In this scenario, Social Security alone might be between $5,000 and $6,000 per month for a married couple which means any retirement savings just need to cover the remaining living expense need which a nest egg of about $1 million should be able to do if invested appropriately, even after taxes are considered. We see retirees all the time where their income potential, or the maximum amount they can spend without running out of money, is much larger than they are currently living on, and they have no idea. If you're planning for retirement, know how much you actually need so you can either retire earlier or at least have the peace of mind that you are financial independent if you'd rather keep working.     Companies Discussed: Honeywell International Inc. (HON), Dominos Pizza, Inc. (DPZ) & Bristol-Myers Squibb Company (BMY)

NCLA is taking a stand in Bristol Myers Squibb Company v. Becerra! We've filed an amicus curiae brief with the U.S. Court of Appeals for the Third Circuit, challenging the Department of Health and Human Services' (HHS) attempt to hold a company's business hostage to force it to give up its constitutional property rights. Our brief argues that this violates the “unconstitutional conditions” doctrine, which protects against indirect violations of constitutional rights. Tune in as NCLA Senior Litigation Counsel joins Mark and Vec to break down this critical legal battle and its broader implications.See omnystudio.com/listener for privacy information.

Dr. Shannon Westin and her guests, Dr. Herbert Duvivier and Dr. Richard Schilsky, discuss the paper “Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study” published in the JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare.  Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in-depth into articles published in the Journal of Clinical Oncology. I am your host, Shannon Westin, GYN Oncologist and Social Media Editor of the JCO. As always, it is my pleasure to serve and bring this information to you.  Today, we will be discussing, “Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.” And this was published in the JCO on August 10th, 2023.  None of the authors have any conflicts of interest to disclose.  Joining me today are two of the authors, Dr. Herbert Duvivier, the principal investigator of this arm of the TAPUR trial. Welcome. Dr. Herbert Duvivier: Thank you.  Shannon Westin: And then, of course, many of you know Dr. Richard Schilsky, who is the former CMO and Executive Vice President of ASCO and a principal investigator on the TAPUR study.   Dr. Richard Schilsky: Thank you, Shannon.  Shannon Westin: So, let's get going. I think the first thing would be great is to level set and make sure everyone knows exactly what this TAPUR basket trial is, the Targeted Agent and Profiling Utilization Registry study. Can you guys give the audience a brief description of the objective of TAPUR and maybe how it came to fruition?  Dr. Richard Schilsky: Sure. This is Richard Schilsky. Maybe I can start with that. The TAPUR study is a prospective, phase II, multi-basket, multi-center genomic-matching trial. Its primary objective is to identify signals of drug activity for targeted agents that are already marketed. But in the TAPUR study they are being used outside of their FDA-approved indication. The study, as you may know, was conceived in 2014, launched in 2016, and is still enrolling patients across the country. Really, the genesis of the study came from the fact that it began at the time where genomic profiling of patients with advanced cancer was becoming more commonplace. Genomic alterations that could be targeted by already marketed drugs were being identified. However, patients and doctors were having difficulty accessing these drugs because they were not used on label and were unlikely to be covered by insurance. And moreover, even if they could access the drugs, there was no organized mechanism to collect outcome data and report on the results of the patient experience receiving that treatment.  So those factors led to the development of TAPUR, which attempts to solve both the drug access problem by having collaborating pharmaceutical companies donate their drugs to the trial so they're available to patients at no cost, but also implements a structured data collection mechanism so all of the relevant clinical outcomes with the patients can be collected and ultimately reported. And that's how TAPUR came about. Shannon Westin: Well, it was so necessary, and I think we do so much of our oncology treatments off-label, but as we get more and more expensive drugs when we move away from chemotherapies and more targeted immunotherapies, it's very hard to get those drugs off label. So this was such a relevant and necessary trial that had to happen, and it's a great example of leadership that you had the vision to put this together through ASCO.  I think the natural next question for me is having not put patients on the TAPUR study, how does a patient join this study? How do they get started? Walk us through that. Dr. Herbert Duvivier: At our institution, normally, all the physicians are aware of the TAPUR trial through internal conversations. When they have patients who have been treated with multiple lines of standard therapy, usually the next step for them is to get NGS testing. We have a research team that reviews all NGS testing for these patients and knows the open arms of the TAPUR trial. And if there happens to be a particular patient who may match with one, they will inform the physician. It is then up to the physician to speak to the patient about that option.  Shannon Westin: Do you have people come looking for the TAPUR trial or are these generally more established patients? Dr. Herbert Duvivier: From my perspective, I think it is usually established patients. Shannon Westin: I think what I love about this trial, and I have spoken about this trial in lectures around baskets, it's such a pragmatic design making it as straightforward as possible to really implement across different centers, whether academic or community, or wherever they are. I guess one of the questions always around these targeted therapies is the molecular selection. How do you make sure that people are being appropriately molecularly selected and how do you decide which testing to utilize?  Dr. Richard Schilsky: As you pointed out, Dr. Westin, the goal of the study from the beginning was to have a very pragmatic design, in a sense to have this study attempt to replicate the way oncologists were deploying precision medicine in their practice. The study has broad eligibility criteria, it has minimum necessary data collection, it uses conventional clinical evaluations, there are no additional clinical evaluations required that are not part of routine clinical care. And it just makes it easy to embed the study into the clinical workflow. The study is based largely at community sites, about 85% of the 268 participating sites are located in smaller communities. The study has a set of genomic matching rules that are listed in the protocol and baked into the IT platform for the study as a rules engine. For every treatment available in TAPUR, there is a set of genomic inclusion and exclusion criteria.  So in essence the way it works, the physician determines that NGS testing is appropriate for their patient and can use any NGS test they want, as long as the test is performed in a CLIA certified, CAP, or New York State-accredited laboratory. They select the test, they select the biospecimen to be tested, they get the results, they look at the results, and they determine if there is a genomic alteration in the patient's tumor that is targeted by one of the study treatments in the TAPUR study. They can enter that into the rules engine, the rules engine will confirm or not that the appropriate alteration of treatment has been selected. If it is confirmed, then the patient can immediately be enrolled in the study if they meet the clinical inclusion and exclusion criteria.  If the rules engine does not confirm the treatment match is appropriate, or in some cases there are multiple possible treatment matches, if there are multiple alterations that can be targeted, or another case is the doctor is simply uncertain about which alteration is best to target, then the clinical site can send that patient case to the TAPUR molecular tumor board. A group of experts convenes weekly that reviews the clinical history, the pathology report, genomic test report, the prior therapy the patient has received, and they make a determination as to whether or not there is an appropriate therapy that's available on TAPUR for the patient. And if not, then are there other potential therapies  that are available that could be considered. That information is sent back to the treating physician who determines whether or not here she feels that treatment option is appropriate for their patient, and if so, the patient can then be enrolled and receive the therapy. Shannon Westin: So awesome. I love the idea. If we don't have an arm for you on our trial, we can help assist you potentially determine an option for your patient outside of that. That's so clever.  Okay. So let's get into this particular arm. Obviously, our audience is quite savvy and are aware of the role of immune checkpoint inhibition across a number of solid tumors. Could you describe what you sought to determine in this particular arm of the TAPUR study?  Dr. Herbert Duvivier: I think one of the most important things to remember about this study is that this study was opened and accruing prior to pembrolizumab becoming FDA approved in, I think, June of 2020. So prior to June of 2020, there was no indication for pembrolizumab in high TMB tumor types and the goal of the study was to determine if pembrolizumab had any overall response rate, duration of responses, progression-free survival, or overall survival advantage over what would be considered standard chemotherapy at that time in patients with high TMB. Dr. Richard Schilsky: Yeah, that's exactly right. And in this paper that we're discussing, we're reporting on two different groups of patients. So there's a group of 28 patients, all with colorectal cancer, all of whom had high tumor mutation burden, as defined by the protocol. And that's one group. Then there's a second, larger group of patients, which is a very heterogeneous group of solid tumor patients. And the reason that that group is reported is there were patients who were being enrolled with multiple different tumor types with high tumor mutation burden. Each tumor type determined a specific, tumor-specific cohort in the study, and they were enrolling at different rates depending upon how common the particular tumor type was. But once the FDA approval for pembrolizumab, for any tumor with a high tumor mutation burden, was granted, then all of those cohorts essentially had to close to new enrollments because there was no longer an off-label use for pembrolizumab in that setting - everything was now on the label.  The result was that we then basically collapsed all of the open cohorts that were not then going to be able to complete into this one large, heterogeneous cohort that's being reported in this paper. And going back to the colorectal results, in the paper, we describe a disease control rate of 31%, an objective response rate of 11%. There were three patients who had partial responses lasting 12, 27, and 97 weeks each. And I think it's important to point out that in this particular cohort, essentially all of the colon cancer patients were microsatellite stable. So that's an interesting nuance here because we know that pembrolizumab is active and has an FDA approval in microsatellite high tumors. But this particular group of patients was essentially all microsatellite stable, suggesting that even in that population, if the tumor also has a high tumor mutation burden, the patient has the potential to respond and benefit from the treatment. Shannon Westin: I found that very intriguing. And, of course, as a gynecologic oncologist that treats endometrial cancer, I'm always thinking about MSI and microsatellite stability. So I was very intrigued by this. We are not seeing a ton of TMB high in our population, but there are some patients that do have that.  So let's talk a little bit about the results for the collapsed all solid tumor group. What did you find there? Dr. Herbert Duvivier: In the histology pool cohort, there were 47 patients representing 21 different tumor types, with a median tumor mutational burden of approximately 13 mutations per megabase with a range of 9 to 228. 40 of 47 patients had MSS disease, microsatellite stable disease. 6 of the 47, MSS was not reported, and 1 case was ambiguous. The disease control rate was about 45%, and the objective response rate was 26%. There were 3 complete responses: 1 in bladder, 1 in parotid, and 1 in squamous cell carcinoma. 9 partial responses and 9 stable disease 16 plus weeks. Of interest in the patients that were responding, 10 out of the 21 patients had POLE or POLD1 mutations, and 9 of the 21 patients had BRCA1 or BRCA2 mutations, although most of those mutations were classified as variants of uncertain significance. Shannon Westin: That's really interesting. We've seen pretty good data for POLE and benefit from immunotherapy, although at least in the GYN tumors and especially in endometrial cancer, those patients usually do well no matter what you do with them. And so they don't often make it to get immunotherapy because they have a complete response up front to their surgeries. So very intriguing to see that driving benefit. I'm just interested to see because it seems like there's a range that you were quoting of what was considered to be TMB high. So did you see a correlation for response to therapy based on how high the tumor mutational burden was in a given tumor or tumor type? Dr. Herbert Duvivier: Yes, actually we did see a moderately negative correlation between maximum percent change from baseline in a tumor and increasing TMB, which indicated an association between a higher TMB and greater shrinkage of tumor lesions. Dr. Richard Schilsky: I should point out, by the way, that when we introduced this arm into the TAPUR study, this high tumor mutation burden arm, as Dr. Duvivier has already pointed out, it was prior to, of course, the FDA approval, and the FDA approval is for tumors that have at least 10 mutations per megabase. It was also prior to the adoption of that threshold of 10, based on work by Friends of Cancer Research and others as sort of the convention for what defined a high tumor mutation burden. So when we put this into TAPUR, we essentially consulted with some of the testing laboratories. We consulted with Merck, the sponsor for pembrolizumab and actually in the TAPUR study, we defined a threshold of 9 mutations per megabase as defining high tumor mutation burden.  Now, as Dr. Duvivier said, there's a broad range of tumor mutation burden represented in this population, and there does seem, if you look at, if the readers want to look at figure 4 in our paper, there does seem to be a general correlation between best response and number of mutations per megabase, which also holds true in a modest way for both progression-free and overall survival. So, TMB is somewhat predictive of favorable outcomes. It's not a perfect biomarker by any means, but generally speaking, if you have enough patients, you can define this sort of trend to support the notion that the more mutations, the greater the likelihood of benefit. Shannon Westin: That makes a lot of sense. One other thing that I just wanted to comment on before we kind of bring the podcast to a close is I was really struck by the high proportion of underrepresented minorities in this arm of TAPUR, and I just would love to hear your thoughts on how the design improves recruiting in this population of patients. Dr. Richard Schilsky: This was a goal of the study, very intentional. When you look at the overall study demographics, there are about 2800 patients now that have been enrolled on TAPUR overall. Almost 12% are black, about 6% are Hispanic, about 4% Asian. The median age is about 64. So it's a slightly older population. The goal always was to enroll a population of patients in TAPUR that was broadly representative of the patients that oncologists treat in practice. In the way we accomplished what we've accomplished, we still have work we can do to improve it. But the clinical sites were carefully selected and vetted. We focused on sites that served a significant fraction of minority patients. We made the eligibility criteria simple and broad, so many of the eligibility criteria that might typically exclude minority populations or older patients from clinical trials are not exclusion criteria in TAPUR. We made the operations of the trial simple, so patients really aren't asked to do much more than what they would normally be asked to do in the course of their routine cancer care. So I think all of those things together have made it possible to attract and enroll a more representative patient population in the study. And we're very gratified by that because when you look at many of the registration trials for many cancer drugs, minorities and older people are terribly underrepresented. So we feel that TAPUR is adding value there and adding useful information. Shannon Westin: I think it's so generalizable and really the way people are practicing, and so to see similar results or concordant results, despite not as much of the rigorous testing and potentially exclusion of certain patient populations is really reassuring and certainly very exciting.  The last question is what's coming next? What other arms are coming soon? And can sites still join? Is this something where it's ongoing enrollment and participation? Dr. Richard Schilsky: So sites can still join. There's a place on the ASCO website where sites can find more information about TAPUR, and there's essentially a form available where sites can indicate their interest in joining the study. And then those sites are then evaluated by the TAPUR study team to determine if they meet the minimum necessary requirements to qualify to join the study. There's a lot more data coming out, many more papers that are in press and being written. There are two abstracts that will be presented in April at the AACR meeting. There are three abstracts that have been submitted for the ASCO annual meeting. So a lot more data to come.  This is a study that, at least hypothetically, could continue in perpetuity as long as we're able to continue to attract new drugs and new treatment combinations onto the TAPUR study platform. So the TAPUR team is always on the lookout for drugs that are about to get an FDA approval and that could be appropriate for the TAPUR study and continue to talk to many pharmaceutical companies about their interest in potentially putting their drugs on the platform. Shannon Westin: Well, great. Thank you both for taking the time. I know you're both incredibly busy.  Again, this has been “Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.” I'm your host, Shannon Westin, and I'm so grateful that you joined us on JCO After Hours. Please check out our other offerings on the website or wherever you get your podcasts. Have an awesome day.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Duvivier's COIs: Speakers' Bureau Company name: Guardant Health Company name: AstraZeneca Company name: Regeneron  Schilsky's COIs: Leadership Company name: Clarified Precision Medicine Company name: Leap Therapeutics Stock and Other Ownership Interests Company name: EQRx Company name: Leap Therapeutics Consulting or Advisory Role Company name: Cellworks Company name: Scandion Oncology Company name: Bryologyx Company name: Illumina Company name: EQRx Company name: Syapse Company name: Zephyr AI Company name: AADi Research Funding Company name: AstraZeneca Company name: Bayer Company name: Bristol-Myers Squibb Company name: Genentech/Roche Company name: Lilly Company name: Merck  

In this episode of the podcast I speak with Uzair Qadeer, the Chief People Officer of the BBC about Enterprise Leadership and how this works in an organisation that not only makes the news, but often is the news. We talk about the work he has been doing with the BBC Executive Committee to develop and enhance their Enterprise Leadership and how he is driving the BBC's people strategy, cultural transformation and organisational change. If you'd like to find out more about how to develop Enterprise Leadership in your Executive Team, or to find out more about the work that we're doing with executive teams more generally, you can reach out here: https://waldencroft.com/contact/ Or sign up for the newsletter here: https://waldencroft.com/newsletter/ Here's some more information about Uzair. Uzair joined the BBC as Chief People Officer in February 2023. He oversees the full spectrum of global human resources capabilities across the BBC Group and is responsible for driving the BBC's short- and long-term employee experience, cultural transformation, and organisational change through the people agenda. Prior to joining the BBC, Uzair worked in a range of senior executive positions. He was previously Chief People Officer at Carbon Health, a US healthcare provider, where he built and oversaw a first-class HR function to lead the company through a dynamic period of transformation. Prior to joining Carbon Health, Uzair was with Alexion Pharmaceuticals where, as Alexion's first Chief Diversity Officer and member of the company's executive committee, he built a global function that elevated employee engagement, created an inclusive environment, and drove innovation for customers through a sophisticated use of diversity and inclusion insights. He has held numerous additional leadership roles, including in Deloitte's Human Capital Consulting practice where he advised clients across various industries and geographies on a variety of human resources topics, and at Bristol Myers Squibb Company where he worked in various roles of increasing responsibilities both in the U.S. and in Italy. Uzair has been a featured public speaker and thought leader on the topics of employee experience, inclusion, and the future of human resources. He received his Master's degree and Bachelor of Arts and Bachelor of Science degrees from Pennsylvania State University.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, hosts Drs. Erin Forster and Ayanna Lewis are joined by Drs. Freddy Caldera and Jana Al Hashash, who were part of the inaugural class of participants in AGA's GI Clinical Trialists Bootcamp program. Today's discussion focuses on how diversifying participation in clinical trials starts with diversifying our workforce. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, hosts Drs. Erin Forster and Ayanna Lewis are joined by Melodie Narain-Blackwell, the founder and president of Color of Crohn's & Chronic Illness (COCCI). COCCI is a nonprofit dedicated to health equity in BIPOC communities that are challenged with digestive diseases and chronic illnesses. Melodie was diagnosed with Crohn's disease at the age of 36, thirty years after her symptoms began, and has become a passionate health advocate for people of color who battle chronic illness. Today's discussion focuses on how we talk about clinical research with patients. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, co-host Dr. Erin Forster is joined by guest Dr. Gabriela Radulescu, vice president of medical research and development at Alimentiv, a contract research organization (CRO) specializing in gastroenterology trials. Dr. Radulescu has more than 20 years of experience working in the pharmaceutical industry across multiple functions, including medical affairs, drug safety and pharmacovigilance, clinical research, real world evidence, and patient support programs. At Alimentiv, Dr. Radulescu provides medical leadership for sponsored clinical trials, operational oversight for R&D projects, and medical input to the business development teams. Today's discussion will explore how CROs are working with investigators and sponsors to increase the diversity of patients enrolling in clinical trials. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, co-host Dr. Erin Forster is joined by guest Kenneth Getz, professor of public health and community medicine and director of the Center for the Study of Drug Development at Tufts University School of Medicine. Ken is also the founder and chairman of the board of directors at CISCRP, a nonprofit dedicated to providing education and information about clinical research. Today's discussion will explore how we can bring awareness of and education on clinical research to the community. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this episode, co-host Dr. Ayanna Lewis is joined by guest Dr. Erica Cohen, an adult gastroenterologist, IBD specialist and director of the IBD Research Program at Capital Digestive Care in Washington, D.C. Today's discussion focuses on the community GI's perspective on clinical trials. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Welcome to our six-part series: Increasing Diversity in IBD Clinical Trials. This program will explore how to become a clinical trialist and increase diversity in IBD clinical trials. In this supersized episode, co-host Dr. Ayanna Lewis is joined by guest Dr. Ryan Stidham, an associate professor at the University of Michigan holding appointments in the departments of medicine and computational medicine. Dr. Stidham is a medical data scientist and has a research program that focuses on the development and testing of new technologies for disease assessment and decision making in gastroenterology and general medicine. Today's discussion will explore how artificial intelligence may help address challenges with participant recruitment for clinical trials, while also discussing the role of AI in the field of gastroenterology more broadly. This series is supported by educational grants from AbbVie Inc.; Amgen; Bristol-Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.

Bristol-Myers Squibb Company, Q3 2023 Earnings Call, Oct 26, 2023

This video is a 10 year financial recap of Bristol-Myers Squibb Company (BMY) and the expected future performance. Income Statement, Balance Sheet and Cash Flow + Strong Growth and Low Debt. Possible Trifecta. Don't Miss This Review!!! "Long ago, Ben Graham taught me that 'Price is what you pay; value is what you get.' Whether we're talking about socks or stocks, I like buying quality merchandise when it is marked down." - Warren Buffett •••••••••••••••••••••••••••••••••••••••••••••••••• Remember to check my website

Bristol-Myers Squibb Company, Q2 2023 Earnings Call, Jul 27, 2023

Synopsis: Liang Schweizer, Ph.D. is the Founder and CEO of HiFiBiO Therapeutics, a clinical-stage global biotech company mobilizing the human immune system to combat disease. The company employs its unique Drug Intelligence Science (DIS®) platform, which combines its proprietary microfluidic single-cell platform with advanced AI/ML-based data analytics, to gain insights into human disease biology at the single-cell level allowing for precise treatment of patients based on their underlying disease mechanisms. HiFiBiO's approach is distinguished from others in industry by applying single-cell science at every stage of drug development, including discovery of novel targets, therapeutic antibodies, and predictive biomarkers, enabling rapid advancement of new therapeutics into the clinic. Liang shares her perspective on the Chinese biotech ecosystem and how it has evolved over the last couple of years. She also discusses how approaches to drug development have changed, specifically around leveraging technology and the intersection of science and technology. She talks about being a CEO for the first time and how she approaches managing globally distributed teams. Interested to learn more? Check out this paper mentioned in our episode: https://tinyurl.com/d3cv9vjt Biography: Liang Schweizer is the Founder, Chairperson and Chief Executive Officer of HiFiBiO Therapeutics. She has over 30 years of research and industry experience with numerous publications and global keynote presentations. She is the co-inventor of 12 immuno-modulatory therapeutic antibodies with over 50 patent publications. She also has contributed to 4 marketed drugs and over 20 clinical candidates. Previously, Liang co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi's Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, she was a director at Bristol-Myers Squibb Company. Liang received a B.S. from the University of Science and Technology of China (USTC) and an M.S. in Microbial Engineering and Chemical Engineering from the University of Minnesota. She earned her Ph.D. in Molecular Biology from the University in Zurich. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC).

In this video, we'll perform a BMY stock analysis and figure out what the company looks like based on the numbers. We'll also try to figure out what a reasonable fair value is for Bristol-Myers Squibb Company. And answer is BMY one of the best dividend stocks to buy at the current price? Find out in the video above! Global Value's Bristol-Myers Squibb Company stock analysis. Check out Seeking Alpha Premium and score an annual plan for just $119 - that's 50% off! Plus all funds from affiliate referrals go directly towards supporting the channel! Affiliate link - https://www.sahg6dtr.com/H4BHRJ/R74QP/ If you'd like to try Sharesight, please use my referral link to support the channel! https://www.sharesight.com/globalvalue (remember you get 4 months free if you sign up for an annual subscription!) Bristol-Myers Squibb Company ($BMY) | Bristol-Myers Squibb Company Stock Value Analysis | Bristol-Myers Squibb Company Stock Dividend Analysis | BMY Dividend Analysis | $BMY Dividend Analysis | Bristol-Myers Squibb Company Intrinsic Value | BMY Intrinsic Value | $BMY Intrinsic Value | Bristol-Myers Squibb Intrinsic Value | Bristol-Myers Squibb Company Discounted Cash Flow Model | Bristol-Myers Squibb Company DCF Analysis | BMY Discounted Cash Flow Analysis | BMY DCF Model (Recorded September 10, 2022) ❖ MUSIC ❖ ♪ "Lift" Artist: Andy Hu License: Creative Commons Attribution 3.0. ➢ http://creativecommons.org/licenses/b... ➢ https://www.youtube.com/watch?v=sQCuf...

Bristol-Myers Squibb Company, Q4 2022 Earnings Call, Feb 02, 2023

Bristol-Myers Squibb Company, Q3 2022 Earnings Call, Oct 26, 2022

Top Geothermal and Medical Stocks podcast includes these articles: “6 Best Geothermal Stocks To Buy”; “12 Best Ethical Stocks To Buy Now”; “The biggest carbon losers”; “Amid Fixed Income Calamity, Green Bonds Look Interesting”; “5 green companies to invest in and why they will multiply your investment by 20x”; plus, UK articles and more Podcast: Top Geothermal and Medical Stocks Transcript & Links, Episode 92, October 21, 2022 Hello, Ron Robins here. Welcome to my podcast episode 92 published on October 21, 2022, titled “Top Geothermal and Medical Stocks” — and presented by Investing for the Soul. Investingforthesoul.com is your site for vital global ethical and sustainable investing mentoring, news, commentary, information, and resources. Remember that you can find a full transcript, and links to content – including stock symbols and bonus material – on this episode's podcast page located at investingforthesoul.com/podcasts. Now if any terms are unfamiliar to you, simply Google them. Also, just a reminder. I do not evaluate any of the stocks or funds mentioned in these podcasts, nor do I receive any compensation from anyone covered in these podcasts. Furthermore, I will reveal to you any personal investments I have in the investments mentioned herein. Additionally, quotes about individual companies are brief so that I can get as many companies covered as possible in the time allowedFwor. Please go to this podcast's webpage for links to the actual articles where you'll find much more great company information. ------------------------------------------------------------- 1) Top Geothermal and Medical Stocks One type of terrific renewable energy getting increasing attention is geothermal. This is an interesting article on some of the top producers. It's titled 6 Best Geothermal Stocks To Buy by Hamna Asim on yahoo.com. Here are some quotes. “Geothermal energy refers to heat from within the sub-surface of the earth… However, electricity generation is possible only near active geothermal regions… We have arranged the list according to the hedge fund sentiment around the securities… assessed from Insider Monkey's database of 895 elite hedge funds tracked as of the end of the second quarter of 2022.  6. Ormat Technologies, Inc. (NYSE:ORA) Hedge Fund Holders: 17 Ormat Technologies was founded in 1965 and is based in Reno, Nevada. The company engages in the geothermal and recovered energy power businesses in the United States, Indonesia, Kenya, Turkey, Chile, Guadeloupe, Guatemala, Ethiopia, New Zealand, and Honduras… JPMorgan analyst Mark Strouse on August 8 raised the price target on Ormat Technologies, Inc. to $97 from $90 and maintained a Neutral rating on the shares… 5. Eversource Energy (NYSE:ES)  Hedge Fund Holders: 32 … is based in Springfield, Massachusetts, operating as a public utility holding company engaged in the energy delivery business… Eversource Energy's Geothermal Pilot Program will generate an affordable and low-carbon source of heating and cooling for residents and businesses… Eversource Energy delivers a 3.38% dividend yield as of October 6.  Mizuho analyst Paul Fremont raised the price target on Eversource Energy to $94 from $91 and reiterated a Neutral rating on the shares. 4. Chevron Corporation (NYSE:CVX) Hedge Fund Holders: 59 Chevron announced in February 2021 that it is making an investment in Baseload Capital AB, a Swedish private investment company engaged in developing and operating low-temperature geothermal and heat power assets. On September 26, Chevron Corporation and Mitsui Oil Exploration Co., Ltd. announced a Joint Collaboration Agreement to survey the technical and commercial suitability of advanced geothermal power generation in Japan… Piper Sandler analyst Ryan Todd on September 12 raised the price target on Chevron Corporation to $190 from $189 and kept an Overweight rating on the shares. 3. Berkshire Hathaway Inc. (NYSE:BRK-B) Hedge Fund Holders: 109 Berkshire Hathaway is a diversified American conglomerate with interests in multiple businesses including insurance, utilities, freight rail transportation, energy, and more. Berkshire Hathaway Energy generates, transmits, stores, and distributes electricity from natural gas, coal, wind, solar, hydroelectric, nuclear, and geothermal sources. Edward Jones analyst James Shanahan upgraded Berkshire Hathaway Inc. to Buy from Hold on September 12. 2. Polaris Renewable Energy Inc. (PIF.TO) Hedge Fund Holders: N/A Polaris Renewable Energy was incorporated in 1984 and is based in Toronto, Canada. The company engages in the acquisition and development of renewable energy projects in Latin America. Polaris Renewable Energy Inc. operates a 72 MW net geothermal facility in Nicaragua, as well as hydroelectric facilities and solar projects… On September 28, National Bank analyst Rupert Merer initiated coverage of Polaris Renewable Energy with an Outperform rating and a C$21 price target. 1. Climeon AB (publ) (STO:CLIME-B.ST) Hedge Fund Holders: N/A Climeon was founded in 2011 and is headquartered in Kista, Sweden. The company provides heat power systems in Sweden and the rest of Europe, as well as Asia. Climeon AB serves the geothermal, industrial processes, oil and gas, and maritime industries. Its Heat Power System technology utilizes low temperature geothermal energy and wasted heat energy emitted from engines and industrial processes to produce electricity.” End quotes. ------------------------------------------------------------- 2) Top Geothermal and Medical Stocks Here's another article by Insider Monkey. This is titled 12 Best Ethical Stocks To Buy Now and is seen on yahoo.com. Here is a quote on their methodology and brief comments on each of their picks. Incidentally, only two are non-medical. “We… ranked them from #12 to #1 based on the number of hedge fund holders in our database that held each stock at the end of Q2 2022. 12. GlaxoSmithKline plc (NYSE:GSK) Hedge Fund Holders: 34 GlaxoSmithKline develops, manufactures and markets pharmaceutical products, vaccines, over the counter medicines and health related consumer products globally. 11. Deere & Company (NYSE:DE) Hedge Fund Holders: 54 Deere & Company manufactures agricultural machinery, heavy equipment, forestry machinery and more. 10. Biogen Inc. (NASDAQ:BIIB) Hedge Fund Holders: 54 Biogen discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. 9. Amgen, Inc. (NASDAQ:AMGN) Hedge Fund Holders: 55 Amgen discovers, develops manufactures and delivers human therapeutics worldwide. 8. Gilead Sciences, Inc. (NASDAQ:GILD) Hedge Fund Holders: 58 Gilead Sciences is a pharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical need. 7. Bristol-Myers Squibb Company (NYSE:BMY) Hedge Fund Holders: 69 Bristol-Myers Squibb Company discovers, develops and markets biopharmaceutical products worldwide… the company offers products for hematology, oncology, cardiovascular, immunology and more. 6. Pfizer Inc. (NYSE:PFE) Hedge Fund Holders: 70 Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide. The company… is also a leader in COVID-19 vaccines. 5. Eli Lilly and Company (NYSE:LLY) Hedge Fund Holders: 70 Eli Lilly and Company discovers, develops and markets human pharmaceuticals worldwide. 4. AbbVie Inc. (NYSE:ABBV) Hedge Fund Holders: 71 AbbVie discovers, develops, manufactures and sells pharmaceuticals worldwide… including potential therapies in blood cancer treatment. 3. Tesla, Inc. (NASDAQ:TSLA) Hedge Fund Holders: 72 Tesla is a leading electric vehicle manufacturer that also manufactures and sells battery energy storage and solar panels. 2. Merck & Co., Inc. (NYSE:MRK) Hedge Fund Holders: 79 Merck & Co. is a healthcare company with two segments, Pharmaceutical and Animal Health. Merck & Co., Inc.'s pharmaceutical segment offers products in areas such as oncology, hospital acute care, immunology, neuroscience and more. 1. Johnson & Johnson (NYSE:JNJ) Hedge Fund Holders: 83 Johnson & Johnson researches and develops and sells products in various healthcare fields worldwide. The company's pharmaceutical segment offers products and researches products for rheumatoid arthritis, inflammatory bowel disease, psoriasis and much more.” End quotes. ------------------------------------------------------------- The biggest carbon losers – by Corporate Knights Now many ethical and sustainable investors review the carbon intensities of companies before considering them for investment. In that light is this article. It's titled The biggest carbon losers. It's by Toby Heaps at Corporate Knights on corporateknights.com. Here are some quotes from the article. “This year, Corporate Knights set out to identify global companies that have decarbonized faster than their peers while simultaneously increasing revenue. Our researchers evaluated the greenhouse gas (GHG) emissions of more than 6,500 publicly traded companies. We eventually whittled the list down to 20 corporations from eight sectors that cut the most carbon over the last decade… Many are far from sustainability leaders. They're among the world's largest oil majors, coal burners and mining corporations. About two-thirds of the GHG reductions achieved by these companies were genuine from the planet's perspective… Italian electricity and gas distributor Enel topped the Carbon Reduction 20 ranking… According to calculations by Corporate Knights, these 20 companies funnelled just 35% of new investments in 2021 toward the sustainable, low-carbon economy, as defined by the Corporate Knights Sustainable Economy Taxonomy… 12 of the 20 funnelled more cash to shareholders and top executives than to growing their low-carbon sustainable business offerings… Note… we didn't include Scope 3.” End quotes. Incidentally, the list and details of the 20 companies are found at the bottom of the article. ------------------------------------------------------------- Amid Fixed Income Calamity, Green Bonds Look Interesting Now let's talk green bonds with this article titled Amid Fixed Income Calamity, Green Bonds Look Interesting. It's by Tom Lydon on etftrends.com. Now some quotes from Mr. Lydon. “Data suggest demand for green bonds is perking, indicating the VanEck Green Bond ETF (NYSEArca: GRNB) could be a fixed income exchange traded fund worthy of evaluation. (The fund) tracks the S&P Green Bond U.S. Dollar Select Index, is down year-to-date, but that negative performance could belie opportunity with green bonds. Additionally, data confirm some investors remain enthusiastic about this still young corner of the global bond market… ‘Companies and governments around the world raised more than $54 billion in green bonds last month, compared with more than $35 billion raised in August, data compiled by Bloomberg show. That's despite overall bond issuance in the U.S. and Europe dropping significantly…' reports David Caleb Mutua for Bloomberg.” End quotes. ------------------------------------------------------------- 5 green companies to invest in and why they will multiply your investment by 20x And, lastly, we have this article titled 5 green companies to invest in and why they will multiply your investment by 20x. It's by Market Trends on analyticsinsight.net. Here are some quotes on each of their picks which include some eco-tokens. “1) First Solar Inc. (ticker: FSLR) With a large manufacturing presence in the U.S., this solar panel builder will be among the biggest winners from the Inflation Reduction Act… The company stands alone in the industry with its differentiated semiconductor and streamlined manufacturing process, which yield unparalleled quality and reliability.  2) Tamadoge Tamadoge is the first meme coin with different features like metaverse, NFT store, and P2E crypto game setup with absolute utility… Since the Tamadoge ecosystem needs less energy to function, it ranks as the best eco-friendly crypto to buy during an energy crisis. 3) Powerledger (POWR) … was an Ethereum token established in 2016/17 that powers the Powerledger platform. It debuted on Coinbase in November 2021, with the token's price rising rapidly even while most cryptocurrencies fell in a market-wide crash.   4) Tesla Inc. (TSLA) Although competition has increased recently in the EV sector, there is still one undisputed king: Tesla… Plus, the company is a two-for-one green investment by making traditional solar panels as well as photovoltaic shingles. 5) IMPT.io IMPT.io connects users with hundreds of impactful environmental projects around the world with the purpose to reduce carbon emissions and help our planet. IMPT.io also engages thousands of the largest retail brands that allocate a specific percentage of sale margin for environmental projects.” End quotes. ------------------------------------------------------------- Other Honorable Mentions – not in any order 1) Title: GIS Named A Top Socially Responsible Dividend Stock on Nasdaq.com. By BNK Invest. 2) Title: 2 Renewable Energy Stocks To Watch This Week on Nasdaq.com. By Joe Samuel. UK article Title The magnificent seven: The top sustainable funds outperforming their sectors on Trustnet.com. By Matteo Anelli. ------------------------------------------------------------- Ending Comment Well, these are my top news stories with their stock and fund tips -- for this podcast: “Top Geothermal and Medical Stocks.” Now, please be sure to click the like and subscribe buttons on Apple Podcasts, Google Podcasts, or wherever you download or listen to this podcast. That helps bring these podcasts to others like you. And please click the share buttons to share this podcast with your friends and family. Let's promote ethical and sustainable investing as a force for hope in these deeply troubled times! Contact me if you have any questions. Thank you for listening. Talk to you next on November 4th. Bye for now. © 2022 Ron Robins, Investing for the Soul

Christopher Posner Chief Executive Officer, President, and Director Mr. Posner has served as our President and Chief Executive Officer since November 2021 and has served as a member of our Board since August 2018. He has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz® and Enbrel®. From July 2017 to October 2021, he served as the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at R-Pharma-US, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at Bristol-Myers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University. Please see korsuva.com/pi for Full Prescribing Information.

Bristol-Myers Squibb Company, Q2 2022 Earnings Call, Jul 27, 2022

Contributor: Aaron Lessen, MD  Educational Pearls: Direct Oral Anticoagulants (DOACs) have surpassed Warfarin and Lovenox® for anticoagulation as they do not require injection and allow for easier discharge. In the ED, they are commonly prescribed after PE or DVT diagnosis.  Common DOACs are Apixaban (Eliquis®) and Rivaroxaban (Xarelto®). There has not been a direct head to head study comparing outcomes.  2 large observational studies evaluated the recurrence of clots and bleeding risk in patients with newly prescribed Eliquis® or Xarelto® for DVT or PE. Both studies found that Eliquis® had superior outcomes.  Further data is required to determine the preferred DOAC. A randomized trial comparing the two DOACs is upcoming with enrollment ending in 2023.  References Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Ann Intern Med. 2022;175(1):20-28. doi:10.7326/M21-0717 Aryal MR, Gosain R, Donato A, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019;3(15):2381-2387. doi:10.1182/bloodadvances.2019000572 Image from: Bristol-Myers Squibb Company. Eliquis 10 Million Patients and Counting. Sec.gov. https://www.sec.gov/Archives/edgar/data/14272/000114036119003478/s002621x16_425.htm. Accessed June 12, 2022.   Summarized by Kirsten Hughes, MS4 | Edited by John Spartz MS4 & Erik Verzemnieks, MD   The Emergency Medical Minute is excited to announce that we are now offering AMA PRA Category 1 credits™ via online course modules. To access these and for more information, visit our website at https://emergencymedicalminute.org/cme-courses/ and create an account.  Donate to EMM today!

This week on Pharm5: Ztalmy (ganaxolone) for CDKL5-CDD seizure disorder Opdualag (nivolumab/relatlimab-rmbw) for metastatic melanoma Missouri HB1677 for PBM transparency COVID-19 linked with increased risk and burden of T2DM APhA elections open until April 18th Connect with us! Listen to our podcast: Pharm5 Watch us on TikTok: @LizHearnPharmD Follow us on Twitter: @LizHearnPharmD References: Ztalmy. Package insert. Marinus Pharmaceuticals, Inc; 2022. Opdualag. Package insert. Bristol-Myers Squibb Company; 2022. Erickson K. Missouri lawmakers seek lower drug prices with plan to regulate pharmacy benefit managers. STLtoday.com. https://www.stltoday.com/news/local/govt-and-politics/missouri-lawmakers-seek-lower-drug-prices-with-plan-to-regulate-pharmacy-benefit-managers/article_c0447e7b-af83-5c53-8dac-bf3eecca0cee.html. Published March 23, 2022. Accessed March 23, 2022. Becker C. State policy options and Pharmacy Benefit Managers (pbms). https://www.ncsl.org/research/health/state-policy-options-and-pharmacy-benefit-managers.aspx#/. Accessed March 23, 2022. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long covid: A cohort study. The Lancet Diabetes & Endocrinology. March 2022:1-11. doi:10.1016/s2213-8587(22)00044-4. Election Information. American Pharmacists Association. https://www.pharmacist.com/apha-elections. Accessed March 24, 2022.

This week we've got a blockbuster panel featuring three of the most experienced and insightful veterans of the luxury world: Karen Katz (former President & CEO of the Neiman Marcus Group, Steve Sadove (former Chairman and CEO of Saks) and Oliver Chen (Managing director and senior equity research analyst at Cowen and Company). We cover a lot of territory, first trying to align on a working definition of what "luxury" really means today and how luxury was evolving pre-COVID. Then we shift into what's next, including our dream team's quick takes on luxury re-commerce, the role of the in-store experience, the importance of multi-brand retail (online and off), sustainability, exclusivity, storytelling and more. We wrap up getting everyone's view on why it's so hard for legacy brands to innovate and  whether .com spin-outs make any sense at all.But first we open up with the top retail stories that caught our attention this past week, with a big focus on what we can take away from Black Friday and Cyber Monday performance as the threat of Omicron looms, more profitless prosperity from Allbirds as they report their first quarterly earnings as a public company, and Amazon's rise to parcel delivery supremacy. About Karen KatzKatz, who is a graduate of the University of Texas, is the former chief executive, president and director of the Neiman Marcus Group. She stepped down from the role in January 2019. Since 2014 she has also been on the board of directors at Under Armour.Katz has worked in a number of key executive and leadership roles at Neiman Marcus since joining the group as a merchandise manager in 1985. Most recently she has leveraged Neiman Marcus' brick and mortar assets to launch an omni-channel strategy that includes merging planning and buying teams for all departments and integrating customers' online and in-store experiences with in-store apps and personalised web dashboards.Under Katz, Neiman Marcus acquired luxury e-commerce site MyTheresa.com, the Munich-based luxury e-tailer. She also expanded MyTheresa's e-commerce offerings to bolster the Neiman Marcus omni-channel strategy and oversaw the opening of the retailer's first New York City flagship in 2018, a seven-story retail project situated in the Hudson Yards in Manhattan's far West Side. About Steve SadoveBetween 2002 and 2013, Mr. Sadove held positions of increasing responsibility with Saks Incorporated, serving as its Chairman and Chief Executive Officer from 2007 to 2013.Prior to joining Saks, Mr. Sadove built a distinguished marketing and consumer products career spanning more than 25 years and held senior positions at companies including General Foods (now Kraft) and Bristol-Myers Squibb Company as President of Clairol. He led Clairol to become the number one hair care business in the United States, relaunched the Herbal Essences brand into a $700 million business and completed the sale of the beauty care business to Procter & Gamble. Mr. Sadove is also a founding partner of JW Levin Management Partners, a private equity firm.Mr. Sadove is a former Chair of the National Retail Federation and serves as an advisor to Mastercard. He serves on numerous community and civic boards including Hamilton College as Chairman of the Board of Trustees and AmeriCares. About Oliver ChenOliver Chen has joined Cowen and Company's Equity Research department as a Managing Director and Senior Equity Research Analyst. He covers over 30 stocks in the Retail & Luxury Sectors.Oliver is a graduate of Georgetown University, The Wharton School at the University of Pennsylvania and is a CFA Charterholder. He also serves on the PhD Retail Research Review committee at the Wharton School's Jay H. Baker Retailing Center. Mr. Chen was recognized in the Wharton School's “40 Under 40” brightest stars alumni list in 2017.Most recently, Mr. Chen was recognized on the 2018 and 2017 Institutional Investor All-America Research team as a top analyst in the retailing/department stores & specialty softlines sector. Mr. Chen was also selected as a preeminent retail influencer as he was named to the National Retail Federation (NRF) Foundation's “2019 List of People Shaping Retail's Future.” Considered an “industry expert,” Mr. Chen frequently appears as a speaker/panelist at key industry events.Steve Dennis is an advisor, keynote speaker and author on strategic growth and business innovation. You can learn more about Steve on his       website.    The expanded and revised edition of his bestselling book  Remarkable Retail: How To Win & Keep Customers in the Age of Disruption is now available at  Amazon or just about anywhere else books are sold. Steve regularly shares his insights in his role as a      Forbes senior contributor and on       Twitter and       LinkedIn. You can also check out his speaker "sizzle" reel      here.Michael LeBlanc  is the Founder & President of M.E. LeBlanc & Company Inc and a Senior Advisor to Retail Council of Canada as part of his advisory and consulting practice.   He brings 25+ years of brand/retail/marketing & eCommerce leadership experience, and has been on the front lines of retail industry change for his entire career.  Michael is the producer and host of a network of leading podcasts including Canada's top retail industry podcast,       The Voice of Retail, plus  Global E-Commerce Tech Talks  ,      The Food Professor  with Dr. Sylvain Charlebois and now in its second season, Conversations with CommerceNext!  You can learn more about Michael   here  or on     LinkedIn. Be sure and check out Michael's latest venture for fun and influencer riches - Last Request Barbecue,  his YouTube BBQ cooking channel!

Bristol-Myers Squibb Company, Q2 2021 Earnings Call, Jul 28, 2021

Bristol-Myers Squibb Company, Q1 2021 Earnings Call, Apr 29, 2021

Bristol-Myers Squibb Company, Q4 2020 Earnings Call, Feb 04, 2021

Bristol-Myers Squibb Company - Q3 2020 Earnings Call - Nov 05, 2020

This episode was supported by funding from Bristol-Myers Squibb Company. ONS member Laura Wood, RN, MSN, OCN®, renal cancer research coordinator at the Cleveland Clinic Cancer Center in Ohio and member of the Cleveland ONS Chapter, joins Chris Pirschel, ONS staff writer/producer, to discuss patient education for immune checkpoint inhibitors, overcoming communication barriers, and the best strategies for successful patient education. Music Credit: "Fireflies and Stardust" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 Episode Notes:  Check out these resources from today's episode: Complete this evaluation for free nursing continuing professional development. Resources Are Available to Guide Management of Immunotherapy-Related Adverse Events Common Terminology Criteria for Adverse Events (CTCAE) Using CTCAE to Report Immunotherapy Adverse Events Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients About Immunotherapy Management of Immunotherapy-Related Toxicities Society for Immunotherapy of Cancer

What if a cutting edge technology saved your life? And then what if you got to be part of a startup company that is working on similar technology to save others' lives? Karen Momper, of Theratome Bio is living that story. This week, Micheal Coleman, PhD, and Karen tell the story of Theratorm Bio and the exciting platform they are working on. Learn about how Theratome Bio is developing a portfolio of products derived from adult stem cell secretions. The future includes exciting potential therapies like stroke treatment and organ preservation during transport. Learn Michael's and Karen's inspiring stories. Resources in this episode: Indiana Center for Biomedical Innovation TheratomeBio.com Theratome Bio on LinkedIn Theratome Bio on Facebook About Michael Coleman, PhD: Michael brings a wealth of research and new drug development experience to Theratome Bio.  He directed multidisciplinary teams at GeneMedicine and Valentis in Houston, Texas, prior to accepting a role with Centelion (a subsidiary of Sanofi-Aventis) as Vice President of R&D.   He there led a team of scientists in discovery, process & clinical development, and regulatory affairs.  Most recently, Michael was President and CEO of InGeneron, a medical device firm committed to driving personal regenerative medicine therapies.  During his tenure InGeneron attained several regulatory approvals in Europe and initiated clinical trials in the US under FDA approval. Michael has dedicated his career to developing new therapies, ushering these innovations through regulatory paths, and ultimately seeing new therapies transitioned into the clinic.  He has also continued to publish research in peer-reviewed journals and maintain a close relationship with leading researchers and clinicians in academia. He earned his BS and MS degrees from Texas A&M, his PhD from Penn State, and completed post-doctoral work at the Baylor College of Medicine. Michael has a passion for the regenerative medicine space.  He's long thought that a cell-free option is where the future of regenerative therapy is headed, and believes that TheratomeTM technology provides the key attributes of product consistency and ease of handling and administration necessary to achieve widespread clinical application.  In his own words, “TheratomeTM technology solves the key issues limiting clinical application of stem cell based therapies.   I am excited for the opportunity to be part of developing this technology that will provide life changing benefits patients and disrupt the field of regenerative medicine.”   Karen earned a B.A. in Chemistry with a minor in Marketing from the University of Dayton.  She completed an Undergraduate Thesis while there, worked for the Office of Admission leading campus tours, and was hired as a new grad to work as a Traveling Student Recruiter. Karen began her career with the Bristol-Myers Squibb Company shortly thereafter.  During her ten years of employment, she served Primary Care and Hospital Sales roles, sold in multiple outpatient and inpatient therapeutic areas, negotiated formulary contracts, earned district, region, and national recognition for sales, and was selected to serve in leadership roles within her district. Since then, Karen has taken on several non-profit initiatives whereby she has initiated a group, raised funding, and marketed and maintained a leadership role in organizations. She has also used her public speaking abilities to fund-raise.  In one such effort, she contributed to the establishment of an in-house Therapeutic Massage Therapy Program to treat Oncology Patients at Oregon Health and Science University (OHSU) Hospital in Portland, Oregon, a cause that was previously only filled by intermittent volunteers. Karen is happily married, and proud mother to two sons. In addition to multiple volunteer roles at her Parish and children's schools, Karen reads live broadcasts for IRIS Radio, a free service that provides audio news and literature for the visually impaired.  Karen is also the survivor of a stem cell transplant (2009), and an autologous stem cell procedure to her hip to reduce the likelihood for need of replacement. These experiences fuel her unique passion for furthering regenerative medicine innovation.

Dr. William Williams, BriaCell’s President & CEO, called in to SmallCapVoice.com, Inc. to discuss BriaCell Therapeutics Corp.’s history, management, advisory board, Bria-IMT™ (SV-BR-1-GM), the Company's lead product candidate as a targeted and safe approach to the management of cancer, and more. Recently, the Company announced the acceptance of a manuscript describing the novel mechanism of action of the Company’s lead product candidate, Bria-IMT™. The findings detailed in the paper provide a rationale for the encouraging clinical results observed with Bria-IMT™ in current and past clinical testing. The publication will appear in Frontiers in Immunology, the 5th most cited journal in Immunology worldwide. Bria-IMT™, also known as SV-BR-1-GM, has caused remarkable reduction of tumor size in some patients with advanced metastatic breast cancer. BriaCell is an immuno-oncology focused biotechnology company developing a targeted and safe approach to the management of cancer. Immunotherapy has come to the forefront in the fight against cancer, harnessing the body's own immune system in recognizing and selectively destroying cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a potent approach with the potential to prevent cancer recurrence. Bria-IMT™ (SV-BR-1-GM), the Company's lead product candidate, is derived from a specific breast cancer cell line. It is genetically engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that activates the immune system. We believe that Bria-IMT™ helps the body to recognize and kill tumor cells by activating T cells that attack the tumor and B cells that produce anti-tumor antibodies. The results of two previous proof-of-concept clinical trials (one with the precursor cell line not genetically engineered to produce GM-CSF and one with Bria-IMT™) produced encouraging results in patients with advanced breast cancer. Most notably, one patient with metastatic breast cancer responded to Bria-IMT™ with substantial reduction in tumor burden including breast, lung, soft tissue and brain metastases. BriaCell is currently conducting a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. In this trial, Bria-IMT™ treatment appeared safe with similar instances of tumor reduction as those observed in the earlier proof-of-concept trials. This trial is listed in ClinicalTrials.gov as NCT03066947. The trial is being conducted along with the co-development of BriaDX™, the Company’s companion diagnostic test. Additionally, the FDA recently approved the roll-over combination study of Bria-IMT™ with pembrolizumab [Keytruda; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers Squibb Company] for patients previously treated with Bria-IMT™ in the Company’s ongoing Phase I/IIa clinical trial in advanced breast cancer. The roll-over trial is listed in ClinicalTrials.gov as NCT03328026. BriaCell is also developing Bria-OTS™, an off-the-shelf personalized Immunotherapy. Bria-OTS™ is a set of cell lines similar to Bria-IMT™ which are being engineered to express pre-manufactured HLA alleles. With a combined total of 15 different alleles Bria-OTS™ is expected to be able to match more than 90% of the US population. BriaCell’s BriaDX™ companion diagnostic reveals patient HLA types. One or two Bria-OTS™ cell lines carrying matching alleles are planned to be administered per patient. Bria-OTS™ eliminates the complex manufacturing logistics required for other personalized immunotherapies and is regarded as a personalized therapy without the need for personalized manufacturing. Yet another item in the BriaCell pipeline is a novel, selective protein kinase C delta (PKCδ) inhibitor. PKCδ inhibitors have shown activity in a number of pre-clinical models of RAS genes’ transformed cancers including bre...